Tebapivat 是一种新型 PK 激活剂，已被 FDA 授予孤儿药资格，用于治疗低风险 MDS 引起的贫血。 Agios Pharmaceuticals 首席医疗官兼研发主管 Sarah Gheuens ...

While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, ...

Telangana NEET MDS provisional final merit list 2024 released at knruhs.telangana.gov.in. Get a direct link here to download ...

Few things are worse than waking up drenched in the middle of the night, one leg hooked outside of the duvet, sweating as if ...

The Ministry of Health and Family Welfare has officially reduced the qualifying cut-off percentile for NEET MDS 2024 by ...

A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid ...

马萨诸塞州剑桥 - Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) 今天宣布，其新型丙酮酸激酶(PK)激活剂tebapivat获得美国食品和药物管理局(FDA)授予的罕见病药物资格认定，用于治疗骨髓增生异常综合征(MDS)。这一认定通常授予用于治疗美国境内患者人数少于200,000人的罕见疾病的药物。 Agios首席医疗官Sarah Gheuens医学博士强调了 ...

It’s countdown time to the 2024 MDS Fuerteventura, the 6th edition taking place from September 28 to October 5th.

Among patients with myelodysplastic syndromes (MDS), treatment with Reblozyl (luspatercept) resulted in at least 12 weeks of ...

周一，Leerink Partners对Geron Corporation (NASDAQ:GERN)的股票进行了首次覆盖，给予"优于大市"评级，目标价为7.00美元。该公司的乐观展望基于Geron的主打产品Rytelo (imetelstat)的潜力，他们认为该产品在治疗低风险骨髓增生异常综合征(LR-MDS)方面可能成为重磅产品。 Rytelo是首创的端粒酶抑制剂，于2024年6月获批用于治疗 ...

Provide a high level overview of treatment approaches for both lower and higher risk MDS. What are the key considerations when selecting between different treatment options for lower risk MDS?

Deutsche Bank has promoted two managing directors to newly created posts as co-heads of investment banking coverage for EMEA, ...